"With this FDA approval, RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal." "The discovery and development of RINVOQ is indicative of AbbVie's long-standing commitment to advancing the science for people living with immune-mediated conditions," said Michael Severino, M.D., vice chairman and president, AbbVie. "The FDA approval marks an important milestone in our pursuit to deliver innovative medicines that advance care for people living with rheumatoid arthritis." While the approval of Rinvoq is good news for AbbVie, the class of drugs may have some safety concerns. Pfizer has also seen some concerns for its JAK inhibitor, Xeljanz (tofacitinib). Earlier this year a post-marketing study raised concerns about pulmonary embolisms for 10mg doses of the RA drug. You may also like Roche scores TGA approval in small cell lung cancer